Research programme: neurological and cancer therapeutics - BIOALVO
Alternative Names: BLV 0801; IDO inhibitorsLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator BIOALVO
- Class
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Portugal
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders in Portugal
- 01 Feb 2011 Preclinical development is ongoing in Portugal